DOCSLIB.ORG

Pharmacy and Poisons (Amendment) Bill 2014 Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacy and Poisons (Amendment) Bill 2014 Contents 《2014 年藥劑業及毒藥 ( 修訂 ) 條例草案》 Pharmacy and Poisons (Amendment) Bill 2014 C172 C173 《2014 年藥劑業及毒藥 ( 修訂 ) 條例草案》 Pharmacy and Poisons (Amendment) Bill 2014 目錄 Contents 條次 頁次 Clause Page 第 1 部 Part 1 導言 Preliminary 1. 簡稱及生效日期 .............................................................................C186 1. Short title and commencement ................................................ C187 第 2 部 Part 2 修訂《藥劑業及毒藥條例》 Amendments to Pharmacy and Poisons Ordinance 2. 修訂《藥劑業及毒藥條例》 .............................................................C188 2. Pharmacy and Poisons Ordinance amended ............................ C189 3. 修訂詳題 ........................................................................................C188 3. Long title amended .................................................................. C189 4. 修訂第 2 條 ( 釋義 ) ........................................................................C188 4. Section 2 amended (interpretation) .......................................... C189 5. 修訂第 3 條 ( 藥劑業及毒藥管理局 ) .............................................C192 5. Section 3 amended (the Pharmacy and Poisons Board) .......... C193 6. 加入第 4B 條 ..................................................................................C194 6. Section 4B added ..................................................................... C195 4B. 《行為守則》及《執業守則》 ...........................................C194 4B. Codes of conduct and codes of practice ................. C195 7. 修訂第 5 條 ( 藥劑師名冊 ) ............................................................C196 7. Section 5 amended (the register of pharmacists) ..................... C197 8. 修訂第 8 條 ( 註冊為藥劑師的資格 ) .............................................C196 8. Section 8 amended (qualifications for registration as pharmacists) ............................................................................. C197 9. 修訂第 9 條 ( 藥劑師註冊證明書 ) .................................................C198 9. Section 9 amended (certificate of registration as a 10. 修訂第 10 條 ( 不當使用註冊證明書 ) ...........................................C198 pharmacist) .............................................................................. C199 11. 修訂第 10A 條 ( 註冊藥劑師沒有執業證明書不得執業 ) ..............C198 10. Section 10 amended (misuse of certificates of registration) ..... C199 11. Section 10A amended (registered pharmacist not to practise without practising certificate) ..................................... C199 《2014 年藥劑業及毒藥 ( 修訂 ) 條例草案》 Pharmacy and Poisons (Amendment) Bill 2014 C174 C175 條次 頁次 Clause Page 12. 修訂第 11 條 ( 獲授權毒藥銷售商 ) ...............................................C198 12. Section 11 amended (authorized sellers of poisons) ................ C199 13. 修訂第 13 條 ( 處所的註冊 ) ..........................................................C200 13. Section 13 amended (registration of premises) ........................ C201 14. 修訂第 15 條 ( 紀律委員會的委出 ) ...............................................C202 14. Section 15 amended (appointment of Disciplinary Committee) .............................................................................. C203 15. 修訂第 16 條 ( 紀律委員會的權力 ) ...............................................C206 15. Section 16 amended (powers of a Disciplinary Committee) .... C207 16. 修訂第 16A 條 ( 紀律委員會在研訊中的權力 ) .............................C214 16. Section 16A amended (powers of Disciplinary Committee 17. 修訂第 17 條 ( 獲授權毒藥銷售商對僱員的作為所負的法律責 at inquiries) .............................................................................. C215 任 ) .................................................................................................C216 17. Section 17 amended (liability of authorized sellers of 18. 修訂第 19 條 ( 關於紀律委員會作出的指示的條文 ) .....................C216 poisons for acts of employees) ................................................. C217 19. 修訂第 22 條 ( 對銷售第 I 部毒藥的限制 ) ....................................C218 18. Section 19 amended (provisions as to directions given by 20. 修訂第 25 條 ( 列載毒藥銷售商 ) ...................................................C218 Disciplinary Committee) .......................................................... C217 21. 修訂第 27 條 ( 毒藥須加上標籤等 ) ...............................................C222 19. Section 22 amended (limitations on sale of Part I poisons) ..... C219 22. 取代第 28A 條 ................................................................................C224 20. Section 25 amended (listed sellers of poisons) ......................... C219 28A. 對進口和出口藥劑製品的限制 .....................................C224 21. Section 27 amended (poisons to be labelled, etc.) .................... C223 23. 修訂第 29 條 ( 訂立規例的權力 ) ...................................................C226 22. Section 28A substituted ........................................................... C225 24. 加入第 29A 條 ................................................................................C236 28A. Restriction on import and export of 29A. 管理局指明格式的權力 ................................................C238 pharmaceutical products ......................................... C225 25. 修訂第 30 條 ( 藥劑業及毒藥上訴審裁處 ) ....................................C238 23. Section 29 amended (power to make regulations) .................... C227 26. 修訂第 31 條 ( 毒藥委員會 ) ..........................................................C238 24. Section 29A added ................................................................... C237 29A. Power of Board to specify forms ............................. C239 25. Section 30 amended (Pharmacy and Poisons Appeal Tribunal) .................................................................................. C239 26. Section 31 amended (Poisons Committee) ............................... C239 《2014 年藥劑業及毒藥 ( 修訂 ) 條例草案》 Pharmacy and Poisons (Amendment) Bill 2014 C176 C177 條次 頁次 Clause Page 27. 修訂第 32 條 ( 在批發銷售以及將物質售予某些人方面所作的 27. Section 32 amended (exemption with respect to sales 豁免 ) .............................................................................................C240 wholesale and sales to certain persons) .................................... C241 28. 修訂第 33 條 ( 罪行 ) ......................................................................C240 28. Section 33 amended (offences) ................................................. C241 29. 修訂第 34 條 ( 罰則 ) ......................................................................C240 29. Section 34 amended (penalty) .................................................. C241 30. 加入第 34A 條 ................................................................................C240 30. Section 34A added ................................................................... C241 34A. 追討收集或化驗毒藥或藥劑製品等的費用及開支 ......C242 34A. Recovery of costs and expenses of collecting or analysing poisons or pharmaceutical products etc. ........................................................................... C243 第 3 部 Part 3 修訂《藥劑業及毒藥規例》 Amendments to Pharmacy and Poisons Regulations 31. 修訂《藥劑業及毒藥規例》 .............................................................C244 31. Pharmacy and Poisons Regulations amended .......................... C245 32. 修訂第 2 條 ( 釋義 ) ........................................................................C244 32. Regulation 2 amended (interpretation) .................................... C245 33. 加入第 2A 條 .................................................................................C244 33. Regulation 2A added ............................................................... C245 2A. 毒藥表 ..........................................................................C244 2A. Poisons List ............................................................. C245 34. 修訂第 3 條 ( 本條例第 22 條的適用範圍只限於附表 1) ...............C246 34. Regulation 3 amended (application of section 22 restricted to the First Schedule) ............................................................... C247 35. 修訂第 5 條 ( 本條例第 22 條引伸應用於批發銷售等及放寬該 條的規定 ) ......................................................................................C246 35. Regulation 5 amended (extension of section 22 to sales wholesale etc. and relaxation of the section) ........................... C247 36. 修訂第 8 條 ( 全面豁免附表 2 的物品及物質 ) ..............................C246 36. Regulation 8 amended (complete exemption for articles and 37. 取代第 15 條 ..................................................................................C246 substances in the Second Schedule) ......................................... C247 15. 毒藥須加上標籤，標明 “Poison 毒藥” 或附表 5 指 37. Regulation 15 substituted ........................................................ C247 明的其他中英字句等 ....................................................C248 15. Poisons to be labelled “Poison 毒藥” or other bilingual text specified in Fifth Schedule etc. .......... C249 《2014 年藥劑業及毒藥 ( 修訂 ) 條例草案》 Pharmacy and Poisons (Amendment) Bill 2014 C178 C179 條次 頁次 Clause Page 38. 修訂第 19 條 ( 毒藥的貯存 ) ..........................................................C248 38. Regulation 19 amended (storage of poisons) ........................... C249 39. 修訂第 22 條 ( 由某些機構供應藥物予門診病人等 ) .....................C250 39. Regulation 22 amended (supply of medicines to out- patients from certain institutions, etc.) ..................................... C251 40. 修訂第 23 條 ( 供應藥物以供在機構內使用等 ) ............................C250 40. Regulation 23 amended (supply of medicines for use in 41. 修訂第 24 條 ( 在機構內貯存毒藥 ) ...............................................C252 institutions, etc.) ....................................................................... C251 42. 修訂第 24A 條 ( 根據本條例第 25 條提出將姓名或名稱載入 41. Regulation 24 amended (storage of poisons in institutions) .... C253 名單內的申請 ) ..............................................................................C252
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Imaging Diagnostics by Combining Contrast Agents
    (19) TZZ Z _T (11) EP 2 907 526 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.08.2015 Bulletin 2015/34 A61K 49/04 (2006.01) A61K 51/04 (2006.01) A61K 49/06 (2006.01) (21) Application number: 15155866.5 (22) Date of filing: 20.06.2008 (84) Designated Contracting States: (72) Inventor: Wiebelitz, Ulrike AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 13158 Berlin (DE) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Kilger, Ute Boehmert & Boehmert (30) Priority: 22.06.2007 EP 07110922 Anwaltspartnerschaft mbB Patentanwälte Rechtsanwälte (62) Document number(s) of the earlier application(s) in Pettenkoferstrasse 20-22 accordance with Art. 76 EPC: 80336 München (DE) 12199299.4 / 2 572 735 12168380.9 / 2 514 442 Remarks: 08774183.1 / 2 170 405 This application was filed on 20-02-2015 as a divisional application to the application mentioned (71) Applicant: mivenion GmbH under INID code 62. 10115 Berlin (DE) (54) Imaging diagnostics by combining contrast agents (57) The present invention relates to the use of a combination of several contrast agents having different imaging properties with respect to imaging representation. EP 2 907 526 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 907 526 A1 2 Description from suspect lesions and to prepare and assess these samples histopathologically. [0001] The present invention relates to the use of a [0005] MRI examination of the female breast has very combination of several contrast agents having different high sensitivity in comparison to other imaging modali- imaging properties.
    [Show full text]
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The
    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
    [Show full text]
  • The Choice of Gadolinium-Based Contrast Agents: a Radiologist’S Responsibility Between Pharmaceutical Equivalence and Bioethical Issues
    S S symmetry Article The Choice of Gadolinium-Based Contrast Agents: A Radiologist’s Responsibility between Pharmaceutical Equivalence and Bioethical Issues Gaia Cartocci 1, Alessandro Santurro 1 ID , Raffaele La Russa 1,2 ID , Giuseppe Guglielmi 3,4, Paola Frati 1,2 and Vittorio Fineschi 1,2,* 1 Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00185 Rome (RM), Italy; [email protected] (G.C.); [email protected] (A.S.); [email protected] (R.L.R.); [email protected] (P.F.) 2 IRCCS Neuromed, Via Atinense 18, 86077 Pozzilli (IS), Italy 3 Department of Radiology, University of Foggia, Viale Luigi Pinto 1, 71100 Foggia (FG), Italy; [email protected] 4 Department of Radiology, Scientific Institute “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Viale Cappuccini 1, 71013 San Giovanni Rotondo (FG), Italy * Correspondence: vfi[email protected]; Tel.: +39-06-49912-722; Fax: +39-06-4455-335 Received: 24 October 2017; Accepted: 17 November 2017; Published: 22 November 2017 Abstract: Contrast Agents (CA) are among the most commonly prescribed drugs worldwide, and are used, with a variety of techniques, to increase and intensify the differences between body tissues and to help radiologist make diagnoses in a fast and precise way. In recent decades, advancements in research have resulted in significant improvements in their composition, and have made them safer and better-tolerated by patients; this notwithstanding, although the currently available CA are generally considered to be safe, their use is not completely without risk. The use of CA faces the radiologist with economic considerations, bioethical dilemmas, and possible profiles of professional responsibility.
    [Show full text]
  • Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017
    Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017 DOTAREM® (gadoterate meglumine) Injection NDA 204781 Guerbet LLC, 821 Alexander Rd, Princeton, NJ 08540 OPTIMARK® (gadoversetamide) Injection NDAs 020937, 020975 & 020976 Liebel-Flarsheim Company LLC, 1034 Brentwood Blvd., Richmond Heights, MO 63117 ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Information provided within this briefing document is based upon medical and scientific information available to date. ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Page 1 / 168 Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document EXECUTIVE SUMMARY Gadolinium-based contrast agents (GdCAs) are essential for use in magnetic resonance imaging (MRI). Although non-contrast-enhanced MRI may be sufficient for use in some clinical conditions, contrast-enhanced MRI (CE-MRI) using GdCA provides additional vital diagnostic information in a number of diseases. It is widely recognized that CE-MRI increases diagnostic accuracy and confidence, and thus can impact the medical and/or surgical management of patients. Based on the chemical structure of the complexing ligand, GdCA are classified as linear (L-GdCA) or macrocyclic (M-GdCA) and can be ionic or nonionic and those characteristics have a dramatic influence on the stability of the GdCA. Dotarem®, a M-GdCA, was first approved in France in 1989. US-FDA approval was obtained in March 2013 for “intravenous use with MRI of the brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity”, at the dose of 0.1 mmol/kg BW.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Table of Contents
    ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE Bracco Diagnostics Inc. Advisory Committee Briefing Document MultiHance (gadobenate dimeglumine) ProHance (gadoteridol) Table of Contents List of Tables .................................................................................................................................. 5 List of Figures................................................................................................................................. 6 Executive Summary........................................................................................................................ 7 1 Introduction ......................................................................................................................... 12 1.1 MultiHance and ProHance: Chemical Names, Structures and Approved Indications .................................................................................................................... 12 1.2 Properties of Gadolinium-based Contrast Agents........................................................ 13 1.3 Problem Statement ....................................................................................................... 15 2 Evidence of Gd Retention in Brain and Body Tissues ........................................................ 16 2.1 Gd Retention in Brain Tissues...................................................................................... 16 2.1.1 Tissue-Sample Studies .........................................................................................
    [Show full text]
  • Art. 31 Gadolinium
    Annex I List of nationally authorised medicinal products 1 Annex IA – medicinal products containing intravenous gadobenic acid, gadobutrol, gadoteric acid, gadoteridol, gadoxetic acid and intra-articular gadopentetic acid and intra-articular gadoteric acid Member State Marketing Invented name INN + Strength Pharmaceutical form Route of EU/EEA authorisation holder administration Austria Bayer Austria GmbH Magnevist Gadopentetate solution for injection intra-aintra-articular use Dimeglumine 1.876mg/Ml Austria Bayer Austria GmbH Dotagraf Gadoteric Acid solution for injection intravenous use 279.32mg/Ml Austria Bayer Austria GmbH Gadovist Gadobutrol solution for injection intravenous use 604.72mg/Ml Austria Bayer Austria GmbH Primovist Gadoxetic Acid, solution for injection intravenous use Disodium 181.43mg/Ml Austria Bracco Imaging S.p.A. Prohance Gadoteridol solution for injection intravenous use 279.3mg/Ml Austria Guerbet Artirem Gadoteric Acid solution for injection intra-articular use 1.397mg/Ml Austria Guerbet Dotarem Gadoteric Acid solution for injection intravenous use 279.32mg/Ml Austria Sanochemia Cyclolux Gadoteric Acid solution for injection intravenous use Pharmazeutika AG 0.5mmol/Ml Austria Bracco Imaging S.p.A. Multihance Gadobenate solution for injection intravenous use Dimeglumine 529mg/Ml Belgium Agfa Healthcare Imaging Dotagita Gadoteric Acid solution for injection intravenous use Agents GmbH 279.32mg/Ml Belgium Bayer SA NV Dotagraph Gadoteric Acid solution for injection intravenous use 279.32mg/Ml 2 Member State Marketing
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Drug Consumption at Wholesale Prices in 2017 - 2020
    Page 1 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A ALIMENTARY TRACT AND METABOLISM 321 590 7 309 580 7 300 278 7 295 060 8 A01 STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01A STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01AA Caries prophylactic agents 663 8 611 11 619 12 1 042 11 A01AA01 sodium fluoride 610 8 557 12 498 15 787 14 A01AA03 olaflur 53 1 54 1 50 1 48 1 A01AA51 sodium fluoride, combinations - - - - 71 1 206 1 A01AB Antiinfectives for local oral treatment 1 266 10 1 101 6 1 052 6 944 6 A01AB03 chlorhexidine 930 6 885 7 825 7 706 7 A01AB11 various 335 21 216 0 227 0 238 0 A01AB22 doxycycline - - 0 100 0 100 - - A01AC Corticosteroids for local oral treatment 113 1 153 1 135 1 143 1 A01AC01 triamcinolone 113 1 153 1 135 1 143 1 A01AD Other agents for local oral treatment 49 0 72 0 104 0 - - A01AD02 benzydamine 49 0 72 0 104 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 30 885 4 32 677 4 35 102 5 37 644 7 A02A ANTACIDS 3 681 1 3 565 1 3 357 1 3 385 1 A02AA Magnesium compounds 141 22 151 22 172 22 155 19 A02AA04 magnesium hydroxide 141 22 151 22 172 22 155 19 A02AD Combinations and complexes of aluminium, 3 539 0 3 414 0 3 185 0 3 231 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 3 539 0 3 414 0 3 185 0 3 231 0 A02B DRUGS FOR PEPTIC ULCER AND 27 205 5 29 112 4 31 746 5 34 258 8
    [Show full text]
  • Application for Inclusion of Gadolinium-Based Contrast Agents to the WHO
    Application for inclusion of Gadolinium‐based contrast agents to the WHO Essential List of Medicines Submitted by Daniel Patiño, PhD (McMaster) Faculty of Medicine University of Antioquia, Medellin, Colombia Holger J. Schünemann, MD, PhD Chair and Professor, Departments of Clinical Epidemiology and Biostatistics Co‐Director, WHO Collaborating Center for Evidence Informed Policy, McMaster University Potential conflicts of interest Dr. Patiño and Dr. Schünemann declare that they have no COI. Date: Dec 15, 2014 1 Application to add Gadolinium‐based contrast agents to the WHO Essential List of Medicines 1. Summary statement of the proposal for inclusion, change or deletion Currently the 18th edition of WHO Model List of Essential Medicines does not include gadolinium‐based contrast agents (Gd‐CAs) under 14.2 radio contrast media classification. Since the introduction of gadopentate dimeglumine in 1988, gadolinium‐based contrast agents have significantly improved the diagnostic efficacy of Magnetic Resonance Image (MRI) (1). Gadolinium‐based contrast agents are intravenous agents used for contrast enhancement with magnetic resonance imaging (MRI) and with magnetic resonance angiography (MRA). The Gd‐CAs are available for different types of MR scan varying from product to product, including liver, brain and whole body scan. This application proposes to add Gd‐CAs for the complementary list of WHO Essential List of Medicines to be used in the detection of lymph node metastases. It will focus on the following ‘general purpose’ Gd‐CAs: gaodopentate dimeglumine, gadodiamide, gadoversetamide, gadobenate dimeglumine, gadoteridol, gadoteric acid, gadobutrol. We will not include the ‘newer’ Gd‐CAs that are organ specific like the hepatobiliary‐specific contrast agents that are available for imaging the liver (e.g., gadoxetic acid).
    [Show full text]
  • Chapter 138A Pharmacy and Poison Regulations.Pdf
    Chapter: 138A PHARMACY AND POISONS REGULATIONS Gazette Number Version Date Empowering section 30/06/1997 (Cap 138, section 29) [1 July 1978] L.N. 145 of 1978 (Originally L.N. 163 of 1975) Part: I PRELIMINARY 30/06/1997 Regulation: 1 Citation 30/06/1997 These regulations may be cited as the Pharmacy and Poisons Regulations. Regulation: 2 Interpretation L.N. 41 of 2007 09/03/2007 (1) In these regulations, unless the context otherwise requires- "antimonial poisons" (含銻毒藥) means organic and inorganic compounds of antimony; "arsenical poisons" (含砷毒藥) means organic and inorganic compounds of arsenic; "British Pharmaceutical Codex" ( 英國藥學藥典), "British Pharmacopoeia" ( 英國藥典), "British National Formulary" (英國國家處方集) and "British Veterinary Codex" (英國獸醫藥方集) include the supplements thereto; "food" (食物) includes a beverage; "medicine for the internal treatment of human and animal ailments" (用於治療人類及動物病患的內服藥物) includes any medicine to be administered by injection, but does not include any mouth-wash, eye-drops, eye- lotion, ear-drops, nasal drops, douche or similar article; "Tribunal" (審裁處) means the Pharmacy and Poisons Appeal Tribunal established by section 30 of the Ordinance; (L.N. 369 of 1980) "veterinary institution" (獸醫機構) means a veterinary hospital, veterinary clinic or other premises where sick animals are treated. (2) In these regulations any reference to an alkaloid shall include a reference to any salt of that alkaloid, and, in a case where the esters of an alkaloid are included in the Poisons List by virtue of the words "its esters", to
    [Show full text]